227 related articles for article (PubMed ID: 35741847)
1. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
3. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
[TBL] [Abstract][Full Text] [Related]
4. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
5. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
Rust K; Spiliopoulou P; Tang CY; Bell C; Stirling D; Phang T; Davidson R; Mackean M; Nussey F; Glasspool RM; Reed NS; Sadozye A; Porteous M; McGoldrick T; Ferguson M; Miedzybrodzka Z; McNeish IA; Gourley C
BJOG; 2018 Oct; 125(11):1451-1458. PubMed ID: 29460478
[TBL] [Abstract][Full Text] [Related]
6. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N
Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
8. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
Yoshihara K; Enomoto T; Aoki D; Watanabe Y; Kigawa J; Takeshima N; Inomata H; Hattori K; Jinushi M; Tsuda H; Sugiyama T
Cancer Sci; 2020 Sep; 111(9):3350-3358. PubMed ID: 32495382
[TBL] [Abstract][Full Text] [Related]
9. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
10. Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Hu-Heimgartner K; Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Vazquez C; Friedlaender A; Vuilleumier A; Bodmer A; Viassolo V; Sandoval JL; Chappuis PO; Labidi-Galy SI
Fam Cancer; 2023 Jul; 22(3):283-289. PubMed ID: 37119509
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
12. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
Sekine M; Enomoto T; Arai M; Yokoyama S; Nomura H; Nishino K; Ikeuchi T; Kuriyama Y; Nakamura S;
J Hum Genet; 2022 May; 67(5):267-272. PubMed ID: 34983974
[TBL] [Abstract][Full Text] [Related]
14. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
15.
Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
17. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
18. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
19. Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation.
Kim JW; Kang HE; Choi J; Yun SG; Jung SP; Bae SY; You JY; Choi YJ; Kim YH; Park KH
Cancer Res Treat; 2023 Jan; 55(1):155-166. PubMed ID: 35681111
[TBL] [Abstract][Full Text] [Related]
20. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE
Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]